Tenaya Therapeutics, Inc. (TNYA)
TNYA moved a median of -0.84% 30 minutes after news, and -0.61% by the close. How TNYA actually reacts to news — the realized, point-in-time move the market made, measured across 258 labeled events over the last three years with zero look-ahead.
TNYA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.24% | 43% | 258 |
| 30-min | -0.84% | 39% | 258 |
| 60-min | -1.10% | 42% | 258 |
| to close | -0.61% | 36% | 253 |
| Middle 50% of TNYA reactions | -3.36% to +1.79% |
|---|---|
| Median reaction (30-min) | -0.84% |
| Measured reactions | 258 |
Half of all Tenaya Therapeutics, Inc. news events land between -3.36% and +1.79% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when TNYA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to TNYA's baseline. Nothing else.
Recent TNYA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form PRE 14A Tenaya Therapeutics, For: Dec 09 | SEC filing · Form PRE | SEC EDGAR | -6.50% | -21.90% | |
| Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy | Press release | GlobeNewswire | +2.42% | +4.99% | |
| Tenaya Therapeutics to Participate in Upcoming September Investor Conferences | Press release | GlobeNewswire | +1.73% | -0.99% | |
| Form 10-Q Tenaya Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.36% | -6.95% | |
| Form 8-K Tenaya Therapeutics, For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | -0.36% | -6.95% | |
| Form S-8 Tenaya Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | -0.36% | -6.95% | |
| Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -0.36% | -6.95% | |
| Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference | Press release | GlobeNewswire | -0.34% | +2.67% | |
| Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.27% | -0.14% | |
| Form 8-K Tenaya Therapeutics, For: Jun 29 | SEC filing · Form 8-K | SEC EDGAR | +0.89% | +9.54% | |
| Form 8-K Tenaya Therapeutics, For: Jun 29 | SEC filing · Form 8-K | SEC EDGAR | -0.86% | -0.11% | |
| Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer | Press release | GlobeNewswire | -0.86% | -0.11% | |
| Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms | Press release | GlobeNewswire | -8.14% | -8.63% | |
| Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026 | Press release | GlobeNewswire | -8.14% | -8.63% | |
| Form 8-K Tenaya Therapeutics, For: May 27 | SEC filing · Form 8-K | SEC EDGAR | -1.58% | -3.79% | |
| Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026 | Press release | GlobeNewswire | -1.74% | +8.09% | |
| Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC | Press release | GlobeNewswire | -0.00% | -4.74% | |
| Form 10-Q Tenaya Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -3.00% | +3.46% | |
| Form 8-K Tenaya Therapeutics, For: May 06 | SEC filing · Form 8-K | SEC EDGAR | -3.00% | +3.46% | |
| Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -3.00% | +3.46% | |
| Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026 | Press release | GlobeNewswire | -0.06% | +0.65% | |
| Form ARS Tenaya Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.36% | -1.44% | |
| Form DEF 14A Tenaya Therapeutics, For: May 27 | SEC filing · Form DEF | SEC EDGAR | -0.36% | -1.44% | |
| Form DEFA14A Tenaya Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -0.36% | -1.44% | |
| Form 10-K Tenaya Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +8.20% | +5.05% | |
| Form 8-K Tenaya Therapeutics, For: Mar 11 | SEC filing · Form 8-K | SEC EDGAR | +8.20% | +5.05% | |
| Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +8.20% | +5.05% | |
| Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy | Press release | GlobeNewswire | -5.17% | +0.79% | |
| Form 8-K Tenaya Therapeutics, For: Mar 04 | SEC filing · Form 8-K | SEC EDGAR | -5.92% | +28.02% | |
| Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics | Press release | GlobeNewswire | -5.92% | +28.02% | |
| Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026 | Press release | GlobeNewswire | +0.18% | -1.43% | |
| Form S-8 Tenaya Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | -5.81% | -8.14% | |
| Form 8-K Tenaya Therapeutics, For: Jan 26 | SEC filing · Form 8-K | SEC EDGAR | +2.23% | +14.15% | |
| Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones | Press release | GlobeNewswire | +1.47% | -0.57% | |
| Form 8-K Tenaya Therapeutics, For: Dec 31 | SEC filing · Form 8-K | SEC EDGAR | -1.30% | -4.16% | |
| Form 8-K Tenaya Therapeutics, For: Dec 11 | SEC filing · Form 8-K | SEC EDGAR | -4.16% | -11.44% | |
| Tenaya Therapeutics Announces Pricing of Public Offering | Press release | GlobeNewswire | -7.59% | -19.05% | |
| Form 8-K Tenaya Therapeutics, For: Dec 11 | SEC filing · Form 8-K | SEC EDGAR | -7.59% | -19.05% | |
| Tenaya Therapeutics Announces Proposed Public Offering | Press release | GlobeNewswire | -7.59% | -19.05% | |
| Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy | Press release | GlobeNewswire | -7.59% | -19.05% | |
| Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC | Press release | GlobeNewswire | -7.59% | -19.05% | |
| Form 10-Q Tenaya Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +11.57% | +18.18% | |
| Form 8-K Tenaya Therapeutics, For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | +11.57% | +18.18% | |
| Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +11.57% | +18.18% | |
| Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy | Press release | GlobeNewswire | +11.57% | +18.18% | |
| Form 8-K Tenaya Therapeutics, For: Nov 07 | SEC filing · Form 8-K | SEC EDGAR | +11.57% | +18.18% | |
| Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025 | Press release | GlobeNewswire | +0.71% | -1.43% | |
| Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference | Press release | GlobeNewswire | +0.45% | -5.41% | |
| Tenaya Therapeutics to Participate in Upcoming October Investor Conferences | Press release | GlobeNewswire | -0.61% | -0.61% | |
| Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.13% | +6.01% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the TNYA section they belong to.
Where else TNYA is measured.
TNYA earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Tenaya Therapeutics, Inc.'s median reaction calculated?
Every labeled TNYA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 258 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 39% of TNYA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does TNYA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.